Pharmacokinetics and Pharmacodynamics of Tebipenem for Multi-Drug Resistant Enterobacteriaceae Posted on June 11, 2018 at 2:29 pm.Written by Spero Therapeutics View Presentation Post navigation The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): A multicenter analysisIn Vitro Activity of Tebipenem (SPR859) Against Penicillin-Binding Proteins of Gram-Negative Bacteria
